BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

817 related articles for article (PubMed ID: 27865446)

  • 1. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a "freeze all" strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg.
    Zhu X; Ye H; Fu Y
    Fertil Steril; 2017 Feb; 107(2):379-386.e4. PubMed ID: 27865446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation.
    Zhu X; Ye H; Fu Y
    Fertil Steril; 2017 Sep; 108(3):505-512.e2. PubMed ID: 28697910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist.
    Lu X; Hong Q; Sun L; Chen Q; Fu Y; Ai A; Lyu Q; Kuang Y
    Fertil Steril; 2016 Nov; 106(6):1356-1362. PubMed ID: 27490046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection.
    Qin N; Chen Q; Hong Q; Cai R; Gao H; Wang Y; Sun L; Zhang S; Guo H; Fu Y; Ai A; Tian H; Lyu Q; Daya S; Kuang Y
    Fertil Steril; 2016 Aug; 106(2):334-341.e1. PubMed ID: 27114329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments.
    Zhu X; Ye H; Fu Y
    Medicine (Baltimore); 2016 Jul; 95(28):e4193. PubMed ID: 27428219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
    Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
    Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.
    Zhu X; Zhang X; Fu Y
    Medicine (Baltimore); 2015 May; 94(21):e909. PubMed ID: 26020402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.
    Kuang Y; Chen Q; Fu Y; Wang Y; Hong Q; Lyu Q; Ai A; Shoham Z
    Fertil Steril; 2015 Jul; 104(1):62-70.e3. PubMed ID: 25956370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
    Yu S; Long H; Chang HY; Liu Y; Gao H; Zhu J; Quan X; Lyu Q; Kuang Y; Ai A
    Hum Reprod; 2018 Feb; 33(2):229-237. PubMed ID: 29300975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial.
    Wang Y; Kuang Y; Chen Q; Cai R
    Trials; 2018 Aug; 19(1):455. PubMed ID: 30134964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles.
    Kuang Y; Hong Q; Chen Q; Lyu Q; Ai A; Fu Y; Shoham Z
    Fertil Steril; 2014 Jan; 101(1):105-11. PubMed ID: 24161646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Different Progestins in Women With Advanced Endometriosis Undergoing Controlled Ovarian Hyperstimulation for
    Guo H; Li J; Shen X; Cong Y; Wang Y; Wu L; Li B; Gao H; Ma M; Zhang W; Mao X; Fu Y; Lyu Q; Chai W; Kuang Y
    Front Endocrinol (Lausanne); 2020; 11():129. PubMed ID: 32265834
    [No Abstract]   [Full Text] [Related]  

  • 13. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of neither recombinant nor urinary luteinizing hormone was associated with an improvement in the outcome of autologous in vitro fertilization/intracytoplasmatic sperm injection cycles under regular clinical settings: a multicenter observational analysis.
    Schwarze JE; Crosby JA; Zegers-Hochschild F
    Fertil Steril; 2016 Dec; 106(7):1714-1717.e1. PubMed ID: 27678033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, assessor-blind, antimüllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta.
    Ishihara O; Klein BM; Arce JC;
    Fertil Steril; 2021 Jun; 115(6):1478-1486. PubMed ID: 33272623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the initiation of progesterone supplementation in in vitro fertilization-embryo transfer outcomes: a prospective randomized controlled trial.
    Gao J; Gu F; Miao BY; Chen MH; Zhou CQ; Xu YW
    Fertil Steril; 2018 Jan; 109(1):97-103. PubMed ID: 29175065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF: A Double-Blind Randomized Crossover Clinical Trial.
    Wang Y; Chen Q; Wang N; Chen H; Lyu Q; Kuang Y
    Medicine (Baltimore); 2016 Mar; 95(9):e2939. PubMed ID: 26945402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can Ratios Between Prognostic Factors Predict the Clinical Pregnancy Rate in an IVF/ICSI Program with a GnRH Agonist-FSH/hMG Protocol? An Assessment of 2421 Embryo Transfers, and a Review of the Literature.
    Merviel P; Menard M; Cabry R; Scheffler F; Lourdel E; Le Martelot MT; Roche S; Chabaud JJ; Copin H; Drapier H; Benkhalifa M; Beauvillard D
    Reprod Sci; 2021 Feb; 28(2):495-509. PubMed ID: 32886340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial.
    Dong J; Wang Y; Chai WR; Hong QQ; Wang NL; Sun LH; Long H; Wang L; Tian H; Lyu QF; Lu XF; Chen QJ; Kuang YP
    BJOG; 2017 Jun; 124(7):1048-1055. PubMed ID: 28276192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.